Nahid Ali , Ph.D, FTWAS, FNA, FASc, FNASc, FAScT, J C Bose National Fellow

Rajaramanna Fellow
Infectious Diseases and Immunology

Research Interest

  • Diagnostic tools for kala-azar and PKDL.
  • Mechanism of immune regulation and drug induced immunomodulation in Indian kala-azar and PKDL.
  • Evaluation of vaccination strategies and protein- and DNA-based candidate  antigens.
  • Studies on immune stimulation pathways by liposomal vaccines.
  • Cationic liposome based combination therapy with existing drugs and novel compounds.
  • Study of host cell signaling during visceral leishmaniasis.
  • Validation of novel drug targets for the treatment of visceral leishmaniasis.
  • Development of strategies for cancer targeting by liposomal formulations.


J C Bose National Fellow
PhD, Calcutta University, 1985

Honours & Awards

  • Awarded three years Postdoctoral Scholarship from AIRC, Italy (2011- 13).
  • Full fellowship to participate in Developmental Neurobiology course, Japan (2012).
  • Awarded 3.5 years full fellowship from SNS, Pisa, Italy for doctoral studies (2007- 10).
  • Fellowship to participate to the Gordon research conferences (GRC), on Mechanisms of epilepsy & neuronal Synchronization, Waterville, USA (2008).
  • Full fellowship to participate in workshop on Gradient & Signaling, Okinawa, Japan (2008).

Patents & Publications

  1. De M, Ghosh S, Sen T, Shadab M, Banerjee I, Basu S, Ali N. A Novel Therapeutic Strategy for Cancer Using Phosphatidylserine Targeting Stearylamine-Bearing Cationic Liposomes. Mol Ther Nucleic Acids. 2018 Mar 2;10:9-27. doi: 10.1016/j.omtn.2017.10.019. Epub 2017 Nov 1.
  2. Sabur A, Bhowmick S, Chhajer R, Ejazi SA, Didwania N, Asad M, Bhattacharyya A, Sinha U, Ali N. Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis. Front Immunol. 2018 Jan 30;9:18. doi: 10.3389/fimmu.2018.00018. eCollection 2018.
  3. Didwania N, Shadab M, Sabur A, Ali N. Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis. Front Immunol. 2017 Dec 21;8:1779. doi: 10.3389/fimmu.2017.01779. eCollection 2017. Review.
  4. Palit P, Mukherjee D, Mahanta P, Shadab M, Ali N, Roychoudhury S, Asad M, Mandal SC. Attenuation of nociceptive pain and inflammatory disorders by total steroid and terpenoid fraction of Euphorbia tirucalli Linn root in experimental in vitro and in vivo model. Inflammopharmacology. 2018 Feb;26(1):235-250. doi: 10.1007/s10787-017-0403-7. Epub 2017 Oct 23.
  5. Shadab M, Jha B, Asad M, Deepthi M, Kamran M, Ali N. Apoptosis-like cell death in Leishmania donovani treated with KalsomeTM10, a new liposomal amphotericin B. PLoS One. 2017 Feb 7;12(2):e0171306. doi: 10.1371/journal.pone.0171306. eCollection 2017.
  6. Ejazi SA, Bhattacharya P, Bakhteyar MA, Mumtaz AA, Pandey K, Das VN, Das P, Rahaman M, Goswami RP, Ali N. Noninvasive Diagnosis of Visceral Leishmaniasis: Development and Evaluation of Two Urine-Based Immunoassays for Detection of Leishmania donovani Infection in India. PLoS Negl Trop Dis. 2016 Oct 14;10(10):e0005035. doi: 10.1371/journal.pntd.0005035. eCollection 2016 Oct.
  7. Bhattacharya P, Ali N. Treatment of visceral leishmaniasis: anomalous pricing and distribution of AmBisome and emergence of an indigenous liposomal amphotericin B, FUNGISOME. J Parasit Dis. 2016 Sep;40(3):1094-5. doi: 10.1007/s12639-014-0607-3. Epub 2014 Nov 1.
  8. Sabur A, Asad M, Ali N. Lipid based delivery and immuno-stimulatory systems: Master tools to combat leishmaniasis. Cell Immunol. 2016 Nov;309:55-60. doi: 10.1016/j.cellimm.2016.07.011. Epub 2016 Jul 21. Review.
  9. Chhajer R, Bhattacharyya A, Didwania N, Shadab M, Das N, Palit P, Vaidya T, Ali N. Leishmania donovani Aurora kinase: A promising therapeutic target against visceral leishmaniasis. Biochim Biophys Acta. 2016 Sep;1860(9):1973-88. doi: 10.1016/j.bbagen.2016.06.005. Epub 2016 Jun 8.
  10. Choudhury ST, Das N, Ghosh S, Ghosh D, Chakraborty S, Ali N. Vesicular (liposomal and nanoparticulated) delivery of curcumin: a comparative study on carbon tetrachloride-mediated oxidative hepatocellular damage in rat model. Int J Nanomedicine. 2016 May 18;11:2179-93. doi: 10.2147/IJN.S101886. eCollection 2016.
  11. Dar AA, Shadab M, Khan S, Ali N, Khan AT. One-Pot Synthesis and Evaluation of Antileishmanial Activities of Functionalized S-Alkyl/Aryl Benzothiazole-2-carbothioate Scaffold. J Org Chem. 2016 Apr 15;81(8):3149-60. doi: 10.1021/acs.joc.6b00113. Epub 2016 Apr 6.
  12. Bhattacharya P, Ghosh S, Ejazi SA, Rahaman M, Pandey K, Ravi Das VN, Das P, Goswami RP, Saha B, Ali N. Induction of IL-10 and TGFβ from CD4+CD25+FoxP3+ T Cells Correlates with Parasite Load in Indian Kala-azar Patients Infected with Leishmania donovani. PLoS Negl Trop Dis. 2016 Feb 1;10(2):e0004422. doi: 10.1371/journal.pntd.0004422. eCollection 2016 Feb
  13. Dar AA, Enjamuri N, Shadab M, Ali N, Khan AT. Synthesis of Unsymmetrical Sulfides and Their Oxidation to Sulfones to Discover Potent Antileishmanial Agents. ACS Comb Sci. 2015 Nov 9;17(11):671-81. doi: 10.1021/acscombsci.5b00044. Epub 2015 Oct 19.
  14. Asad M, Bhattacharya P, Banerjee A, Ali N. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B. BMC Infect Dis. 2015 Apr 17;15:188. doi: 10.1186/s12879-015-0928-6.
  15. Ali N, Nakhasi HL, Valenzuela JG, Reis AB. Targeted Immunology for Prevention and Cure of VL. Front Immunol. 2014 Dec 19;5:660. doi: 10.3389/fimmu.2014.00660. eCollection 2014.
  16. Sinha R, Roychoudhury J, Palit P, Ali NCationic liposomal-sodium  stibogluconate (SSG): A potent therapeutic tool for the treatment of SSG-sensitive and -resistant Leishmania donovani infection. Antimicrobial Agents and Chemotherapy, 2014, pii: AAC.03305-14. [Epub ahead of print].
  17. Das A. and Ali N. Combining cationic liposomal delivery with TLR4 ligand for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protection. PLOS Neglected Tropical Diseases. 2014, 8(8), 1-17.
  18. Chhajer R and Ali N. Genetically modified organisms and visceral leishmaniasis. Frontiers in Immunology, 2014, 5, 1-10.
  19. Md Asad and Ali N. Dynamicity of immune regulation during visceral leishmaniasis. Proc Indian National Science Academy, 80 No. 2 June 2014 pp.
  20. Bhowmick S, Ravindran R, Ali N. IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine. BMC Microbiology. 2014, 14, 1-12.
  21. Bhattacharya P, Ali N. Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical, 2013, 46(2), 128-134.
  22. Ejazi SA, Ali N. Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects. Expert Review of Anti-Infective Therapy, 2013, 11(1), 79-98.
  23. Das A and Ali N. Vaccine development against Leishmania donovani. Frontiers in Microbial Immunology, 2012, 3,1-19.
  24. Palit P, Hazra A, Maity A, Vijayan RS, Manoharan P, Banerjee S, Mondal NB, Ghoshal N, Ali NDiscovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 2012, 56, 432-445.
  25. Ravindran R, Maji M, Ali N.  Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Molecular Pharmaceutics, 2012, 9, 59-70.
  26. Mazumder S, Maji M and Ali NPotentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection. PLoS Neglected Tropical Diseases, 2011, 5, 1-13.
  27. Palit P, Hazra A, Maity A, Vijayan RS, Manoharan P, Banerjee S, Mondal NB, Ghoshal N, Ali NDiscovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 2012, 56, 432-445.
  28. The Working Group on Research Priorities for Development of Leishmaniasis VaccinesCosta CHPeters NCAli NMaruyama SRde Brito EC JrSantos IK. Vaccines for the leishmaniases: proposals for a research agenda.  PLos Neglected Tropical Diseases, 2011, 5(3), 1-9.
  29. Saha S,  Goswami R, Pramanik N, Guha SK, Saha B, Rahman M, Mallick S, Modak  D, Silva FO, Mendonca IL, Costa DL, Costa CHN, and Ali N. Development and evaluation of Leishmania donovani Promastigote membrane antigen-based serodiagnosis of visceral leishmaniasis and post Kala-azar dermal leishmaniasis. Emerging Infectious Diseases, 2011, 17, 1304-1306.
  30. Mazumder, S, Maji M, Das, A and Ali N. Potency, efficacy and durability of DNA/DNA, DNA /protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c Mice. PLoS ONE, 2011, 6, 1-15.
  31. Banerjee, A., De, M., and Ali N. Combination therapy with paromomycin associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation. Antimicrobial Agents and Chemotherapy, 2011, 55, 1661-1670.
  32. Mondal S, Bhattacharya P and Ali N. Current diagnosis and treatment of visceral leishmaniasis. Expert Review on Anti-Infective Therapy, 2010, 8, 919-944.
  33. Mondal S, Bhattacharya P, Rahaman M, Ali N and Goswami R. P. A curative immune profile one-week after treatment of Indian kala-azar patients predicts success with short-course liposomal amphotericin B therapy. PLos Neglected Tropical Diseases, 2010, 4, 1-8.
  34. Sinha R, Sengupta A, Ali N and Gupta P. N. Is PGL-I really a specific antigen for leprosy? Clinical Infectious Diseases, 2010, 50, 937-938.
  35. Bhowmick SMazumdar TSinha R and Ali N. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani. Journal of Controlled Release, 2010, 141, 199-207.
  36. Bhowmick S., and Ali N. Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PLoS ONE. 2009, 4, 1-10.
  37. Banerjee A., De M., and Ali N.  Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. Journal of Immunology, 2008, 181, 1386-1398.
  38. Bhowmick S., and Ali NRecent developments in leishmaniasis vaccine delivery systems. Expert Opinion on Drug Delivery. 2008, 7, 789-803.
  39. Banerjee A., Roychoudhury J., and Ali NStearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine. Journal of Antimicrobial Chemotherapy, 2008, 61, 103-110.
  40. Palit P., and Ali N. Oral Therapy with Amlodipine and Lacidipine, 1, 4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis. Antimicrobial Agents Chemotherapy. 2008, 52, 374-377.
  41. Saha, S., Mondal, S., Ravindran, R., Bhowmik, S., Modak, D., Mallick, S., Rahman, M., Kar, S., Goswami, R., Guha, SK., Pramanik, N., Saha, B., Ali N. IL-10 and TGF-β mediated susceptibility in Post-kala-azar-dermal leishmaniasis: The significance of amphotericin B in the control of Leishmania donovani infection in India. Journal of Immunology, 2007, 179, 5592-5603.

Gandhi S, Tripathi PP. FTO/AuNPs- based nanosensor for Chlorpyrifos detection in fruits and vegetables”. Patent application number 2017/11044750, National filing date 14 December 2017.